Malignant epithelial ovarian tumours account for approximately 40% of ovarian malignancies. They are characterised by a wide clinical spectrum ranging from the relatively 'innocent' borderline tumours to the fatal carcinomas. The biological differences between these groups of tumours are reflected in prognostic variables and treatment principles (Friedlander and Dembo, 1991) . The tumour stage, the histological type and grade and the mass of residual tumour after initial surgery are widely correlated with prognosis. Recently, quantitative morphometric evaluation of cell and tissue features have been shown to provide objective and reproducible data in the diagnosis and prognosis of these malignancies (Friedlander and Dembo, 1991) .
Previous studies have shown that morphometric features have prognostic value in borderline and malignant ovarian tumours (Baak, 1991) . Among them mitotic activity index and volume percentage epithelium (VPE) are the most important in classifying patients with borderline tumours and early cancers (FIGO I) (Baak et al., 1981 (Baak et al., , 1985 (Baak et al., , 1987 (Baak et al., , 1992 Haapasalo et al., 1989) . In the late stages (FIGO III and IV) , it is important to identify the small number of patients with favourable prognosis (Friedlander and Dembo, 1991; Baak et al., 1992; Rollanson, 1992) .
The aim of this study is to assess the value of morphometric features in predicting survival and response to chemotherapy treatment in 60 (Table I ). They were treated by hysterectomy (where possible) and debulking procedure followed by cisplatin in combination with cyclophosphamide chemotherapy (100 Mug m 2 cisplatin with adequate pre-and posthydration and 500 mg m-2 cyclophosphamide every 3 weeks for six cycles). They were grouped as having residual disease if the diameter of the largest residual mass was >2cm and/or if they had 20 or more sites of disease and nonresidual disease (<2 cm). We also classified them according to histological type and grading (Table I) .
Patients were followed up for at least 5 years or until death. Survival or not at 5 years was used as the most objective criterion (Table I) . Concerning response to chemotherapy, they were classified in two groups, those with complete regression of the disease and those with partial, stable or progressive disease.
Paraffin blocks from the primary tumour obtained from the pathological files were used. Tissue was routinely fixed in 4% buffered neutral formaldehyde. Morphometric analysis was applied on 5 gtm sections stained with haematoxylin and eosin. The fields were selected with the method described in details by Fleege et al. (1991) . They were fields without inflammation, necrosis or calcification and those selected were the most cellular, with the severest atypicality and highest mitotic rate. In these selected fields, the nuclear area, nuclear perimeter, shortest and longest nuclear axis and nuclear roundness were estimated at a magnification of x 787 (objective x 63, numerical aperture 12.5). In each case 100 nuclei were evaluated in the representative sections and their mean and standard deviations were calculated. Table III .
To find the characteristics with the highest association with survival in a multivariate context two approaches were followed: (a) logistic regression (Cox, 1970; Vlachonikolis and Marriott, 1982) and (b) discriminant analysis (Morrison, Vlachonikolis and Marriott, 1982) . Both approaches were used stepwise. Actual survival times were analysed as follows. (a) Survival curves (Kaplan and Meier, 1958) were analysed for each feature or characteristic separately using the Mantel-Cox statistic, better known as the log-rank test statistic (Kalbfleisch and Prentice, 1980 (Cox, 1972; Kalbfleisch et al., 1980) . Similar statistical analyses were carried out with respect to response to chemotherapy. The computations for the statistical analyses were carried out using software packages EGRET (1993) and SPSS (1992) . Time after operation (months) Tables VI and VII. Multivariate analysis (discriminant analysis and logistic regression) of our data revealed the following best combination of prognostic features: mean nuclear area, mean nuclear longest axis and mean nuclear shortest axis. The resulting optimum prognostic score is as follows: OPS = 292.9 + (0.076 x mean nuclear area) -(4.722 x mean nuclear longest axis) -(3.789 x mean nuclear shortest axis) when the patients with positive value of OPS are expected to benefit from a cisplatin combination chemotherapy in contrast to those with negative OPS, who will not.
Discussion
The 5 year survival rate for ovarian carcinomas depends on the stage of the disease: 70% for stage I, 25% for stage II, 12% for stage III, 0% for stage IV (Friedlander et al., 1991) . Adjuvant chemotherapy is therefore indicated especially for (Baak et al., 1981 (Baak et al., , 1985 (Baak et al., , 1986a (Baak et al., , 1986b (Baak et al., , 1988 Haapasalo et al., 1989 Haapasalo et al., , 1991 (Figures 6 and 7) . These findings are in accordance with those reported in the literature (Baak et al., 1988; Haapasalo et al., 1989) . Regarding treatment with cisplatin, these features were found not quite significant when used for the identification of patients treated with cisplatin. Many of these patients survived even if they did not respond to the regimen used perhaps because of different cell biological mechanisms.
Another factor of great importance is the size of the residual tumour (Figure 2 ). The prognosis, as is generally accepted, was found to be favourable if the diameter of the largest residual mass did not exceed 2 cm and/or if there were fewer than 20 sites of disease, regardless of the bulkiness of the disease.
Our results also indicate that nuclear size (Figures 3-5) is an important predictor of the response of tumour to cisplatin chemotherapy. In this aspect the results are in agreement with those of Baak et al. (1988) , although the regimen and dosage of treatment of our patients is different. Many authors have compared the two regimens (cisplatin, cyclophosphamide and doxorubicin used by Baak's group and cisplatin, cyclophosphamide). Some of them were unable to demonstrate any difference in overall response rate, in rate of pathological response and in survival (Edmonson et al., 1985; Neijt et al., 1987; Omura et al., 1989) . Others reported higher rate of complete response or improved survival using cisplatin, cyclophosphamide and doxorubicin (Jakobsen et al., 1985; Bruzzone et al., 1990) . It is difficult to compare the results of these studies because of the different dose intensities used. It is clear that the combination of cisplatin with cylcophosphamide may produce as high a response rate as combinations with other drugs (doxorubicin, hexamethylmelamine) without their potential cardiac or neurological side-effects.
It appears therefore that nuclear dimension is a significant predictor regardless of the dosage or the regimen used, provided that cisplatin is included.
